Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹1,211Prev. Close
₹1,210Turnover(Lac.)
₹34.99Day's High
₹1,220Day's Low
₹1,202.452 Week's High
₹1,59552 Week's Low
₹728Book Value
₹0Face Value
₹10Mkt Cap (₹ Cr.)
1,160.24P/E
52.89EPS
22.82Divi. Yield
06 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
1 Sep 2023
12:00 AM
BookCloser
1 Sep 2023
12:00 AM
AGM
Announcement Date: 01 Sep, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 9.61 | 9.61 | 9.61 | 9.61 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 86.64 | 67.85 | 53.8 | 46.83 |
Net Worth | 96.25 | 77.46 | 63.41 | 56.44 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Revenue | 79.45 | 58.04 | 50.56 | |
yoy growth (%) | 14.79 | 21.4 | ||
Raw materials | -43.44 | -30.44 | -27.18 | |
As % of sales | 54.68 | 52.44 | 53.75 | |
Employee costs | -6.05 | -3.41 | -1.88 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 9.88 | 7.46 | 6.83 | |
Depreciation | -5.26 | -2.57 | -2.42 | -1.85 |
Tax paid | -2.9 | 0.24 | -0.07 | |
Working capital | 6.55 | 5.39 | -7.9 | 17.2 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.79 | 21.4 | ||
Op profit growth | 8.99 | 29.86 | ||
EBIT growth | 4.45 | 29.28 | ||
Net profit growth | 14.05 | 58.42 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 295.71 | 227.11 | 183.84 | 116.12 | 90.81 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 295.71 | 227.11 | 183.84 | 116.12 | 90.81 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 1.36 | 0.75 | 0.76 | 0.5 | 0.41 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,526.8 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,592 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,486 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,112.2 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,440 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Balwant Singh.
Joint Managing Director
Varun Batra
Chairperson & M D
Rahul Batra
Independent Director
Manmohan Khanna
Independent Director
Rohit Parti
Company Sec. & Compli. Officer
Rajni Brar
Whole-time Director
Seema Chopra
Whole-time Director
Ashutosh Shukla
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Beta Drugs Ltd
Summary
Beta Drugs Limited was incorporated as a private limited company with the name Beta Drugs Private limited at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to Beta Drugs Limited on August 11, 2017 Beta Drugs is a part of Adley Group. Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India. The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014. The company is primarily engaged in the manufacturing of oncology products. The Companys products range from anti-cancer tablets, capsules, injections and lyophilized injections. The Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease. The Company set up the first Oncology Unit in Adley Formulations Pvt Ltd. in 2008. It set up a new state of the art manufacturing facility for oncology formulations in 2014; developed in-house Albumin bound Paclitaxel in 2015; started in-house API Plant - Adley Labs in 2017. In October, 2017, the Company came up with a Public Issue of 22,96,000 Eq
Read More
What is the Beta Drugs Ltd share price today?
The Beta Drugs Ltd shares price on nse is Rs.₹1206.85 today.
What is the Market Cap of Beta Drugs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Beta Drugs Ltd is ₹1160.24 Cr. as of 03 Jul ‘24
What is the PE and PB ratio of Beta Drugs Ltd?
The PE and PB ratios of Beta Drugs Ltd is 52.89 and 10.00 as of 03 Jul ‘24
What is the 52 Week High and Low of Beta Drugs Ltd?
The 52-week high/low is the highest and lowest price at which a Beta Drugs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Beta Drugs Ltd is ₹728 and ₹1595 as of 03 Jul ‘24
What is the CAGR of Beta Drugs Ltd?
Beta Drugs Ltd's CAGR for 5 Years at 67.45%, 3 Years at 51.61%, 1 Year at 55.13%, 6 Month at -14.79%, 3 Month at -8.07% and 1 Month at 1.63%.
What is the shareholding pattern of Beta Drugs Ltd?
The shareholding pattern of Beta Drugs Ltd is as follows:
Promoters - 66.73 %
Institutions - 0.38 %
Public - 32.88 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
